Which AML subtype is strongly associated with disseminated intravascular coagulation at presentation due to promyelocyte proliferation?

Get ready for the CAMLPR Hematology Test. Use our quizzes, flashcards, and detailed explanations to enhance your understanding. Prepare confidently for your exam!

Multiple Choice

Which AML subtype is strongly associated with disseminated intravascular coagulation at presentation due to promyelocyte proliferation?

The main concept is that acute promyelocytic leukemia (the M3 subtype) has a strong tendency to cause disseminated intravascular coagulation right at presentation. This happens because the abnormal promyelocytes accumulate and release large amounts of procoagulant and fibrinolytic substances from their dense granules, including tissue factor and cancer procoagulant. When these factors flood the bloodstream, they trigger widespread coagulation and subsequent consumption of clotting factors, leading to DIC with bleeding risk. This characteristic is tied to the biology of acute promyelocytic leukemia, where a chromosomal translocation t(15;17) creates the PML-RARα fusion, blocking maturation and resulting in an overabundance of promyelocytes loaded with these procoagulant contents. While other AML subtypes can have coagulation abnormalities, the association with DIC driven by promyelocyte proliferation is most classic for M3. In clinical practice, recognizing this pattern is crucial because it prompts urgent management with all-trans retinoic acid to relieve the differentiation block and reduce the coagulopathy, along with supportive care.

The main concept is that acute promyelocytic leukemia (the M3 subtype) has a strong tendency to cause disseminated intravascular coagulation right at presentation. This happens because the abnormal promyelocytes accumulate and release large amounts of procoagulant and fibrinolytic substances from their dense granules, including tissue factor and cancer procoagulant. When these factors flood the bloodstream, they trigger widespread coagulation and subsequent consumption of clotting factors, leading to DIC with bleeding risk.

This characteristic is tied to the biology of acute promyelocytic leukemia, where a chromosomal translocation t(15;17) creates the PML-RARα fusion, blocking maturation and resulting in an overabundance of promyelocytes loaded with these procoagulant contents. While other AML subtypes can have coagulation abnormalities, the association with DIC driven by promyelocyte proliferation is most classic for M3.

In clinical practice, recognizing this pattern is crucial because it prompts urgent management with all-trans retinoic acid to relieve the differentiation block and reduce the coagulopathy, along with supportive care.

More practice questions